Studies have shown that transdermal nitroglycerin does not have a significant effect on hot flashes in postmenopausal women.
In the first 5 weeks, the frequency of occurrence decreased by about once a day, but when the dosing cycle was increased to 12 weeks, there was no statistically significant difference from the placebo group.
The results of a study on transdermal nitroglycerin treatment for women with postmenopausal hot flashes conducted by researchers including Allison Hwang of the University of California Medical School, USA, were published in the international journal JAMA Internal Medicine on the 5th (doi:10.1001/jamintered.2023.1977).
About 70% of postmenopausal women experience hot flashes in the face and neck area due to changes in hormone secretion and the skin turns red.
Since the symptoms themselves are caused by estrogen deficiency, hormone replacement therapy that administers estrogen can be used, but in this case, attention is focused on non-hormonal therapies because of the increased risk of venous thrombosis, stroke, and cardiovascular disease.
As physiological studies revealed that nitric oxide is a key factor in mediating vasodilation associated with hot flushes, the researchers hypothesized that inducing nitrogen tolerance with nitroglycerin administration could have an effect on vasomotor symptoms.
The researchers divided participants who reported seven or more hot flashes per day during menopause or postmenopause into two groups: one group received a transdermal nitroglycerin 0.2-0.6 mg/h patch (n=65) and the other group received a placebo (n=69). was administered for 12 weeks to examine the degree of symptom relief.
Participants reported an average of 11 hot flashes and 8.4 severe hot flashes per day.
As a result of the analysis, in the group that applied the transdermal nitroglycerin patch for 5 weeks, the frequency of hot flushes per day decreased by 0.9 times, and severe hot flushes by 1.1 times.
On the other hand, when the duration of treatment was increased to 12 weeks, there was no significant difference in the frequency of occurrence from the placebo group.
Compared to the placebo group, the group using the transdermal nitroglycerin patch reduced hot flashes by an average of 0.1 times per day, and severe hot flashes by 0.5 times, and no significant reduction was observed.
In an analysis combining 5- and 12-week data, there was no significant change in incidence compared to the placebo group.
In addition, a negative effect was observed in the nitroglycerin group, with 47 patients (67.1%) in the nitroglycerin group and 4 patients (5.6%) in the placebo group reporting headaches in the first week of administration.
“This randomized clinical trial confirmed that transdermal nitroglycerin administration did not result in sustained improvement in the frequency or severity of hot flashes compared to placebo,” the researchers said. concluded that
2023-06-07 02:58:15
#Hot #flushes #menopause #nitroglycerin #patch #therapy #effect
